Main Administrative Core

主要行政核心

• 批准号: 10264965
• 负责人: ANNE M MURRAY
• 金额: $ 6.12万
• 依托单位: HENNEPIN HEALTHCARE RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-07-15 至 2024-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10264965
• 关键词: Accreditation; African American; Age; Aging; Alzheimer' s Disease; Alzheimer' s disease related dementia; Area; Aspirin; Australia; Cardiovascular Diseases; Cessation of life; Characteristics; Classification; Clinical; Clinical Data; Cognitive; Communication; Contracts; Country; Coupled; Data; Data Linkages; Data Set; Dementia; Documentation; Dose; Elderly; Ensure; Ethics; Event; Exposure to; Female; Fostering; Funding; Gender; Goals; Grant; Health; Heart failure; Hemorrhage; Hispanics; Impaired cognition; Infrastructure; International; Intervention; Knowledge; Leadership; Life; Logistics; Longevity; Longitudinal Studies; Longitudinal cohort study; Malignant Neoplasms; Mediation; Minority; Monitor; Outcome; Participant; Persons; Procedures; Randomized; Registries; Research; Resources; Site; Societies; Standardization; Stroke; Testing; Training; United States; adjudication; aged; aging population; cancer prevention; cohort; disability; experience; follow-up; insight; nonalzheimer dementia; operation; physically handicapped; primary endpoint; secondary endpoint; success

ASPREE-XT BI-NATIONAL ADMINISTRATIVE CORE – SUMMARY / ABSTRACT The ASPirin in Reducing Events in the Elderly (ASPREE) study successfully established a cohort of 19,114 healthy older adults in the U.S. and Australia who were free of Alzheimer’s disease and related dementias (ADRD), cardiovascular disease, and significant physical disability at baseline, and tested whether the exposure to 5 years of low-dose aspirin (LDA) would prolong dementia-free and disability-free survival. Although the intervention period has ended, the establishment of this large and diverse cohort, coupled with unprecedented findings from the intervention period, has created a rare opportunity for continued surveillance of important health outcomes and the antecedents that jeopardize disability-free survival in this aging population; especially ADRD and cancer. Personal health information will be collected annually from participants, and major clinical events will be confirmed through case documentation prepared for expert adjudication of ADRD (and sub-type classification into Alzheimer’s disease and non- ADRD), cancer (incident, metastatic, type, stage and death), and other key health outcomes including death. Observational follow-up of large, long-term aging studies such as ASPREE benefit from continuity, experience and leadership with ADRD expertise. In this funding request, the ASPREE leadership team proposes to extend follow-up of the participants in both the U.S. and Australia for an additional five years (i.e., ‘ASPREE-XT’), which will greatly enrich an already unique, and highly valuable international research asset focused on prolonging healthy independent life in the elderly, free of dementia and disability. The infrastructure needed to accomplish this will rely on the continuity, leadership, and experience of the U.S. and Australian Coordinating Centers that have proven their success in the ASPREE trial through the exemplary study conduct and completion. This includes bi-national standardized training and accreditation to ensure the consistent administration of the annual cognitive battery and triggered dementia assessments which include the Alzheimer's Disease Assessment Scale cognitive subscale. The Bi-National Administrative Core will deploy the infrastructure and governance necessary to accomplish the aims of the ASPREE-XT longitudinal cohort study, including to understand the legacy effects of low dose aspirin on cognitive decline, ADRD, disability and cancer prevention. The overarching goal of the Bi-National Administrative Core is to foster the dynamic exchange of information, ideas, and data arising from all Cores to provide insight into factors that may extend dementia-free and disability-free survival of older adults.

ASPREE-XT BI-MEDICAL CORE -总结/摘要 ASPirin减少老年人事件（ASPREE）研究成功地建立了一个由美国和澳大利亚的19，114名健康老年人组成的队列，他们在基线时没有阿尔茨海默病和相关痴呆（ADRD），心血管疾病和显著的身体残疾，并测试了暴露于5年低剂量阿司匹林（LDA）是否会延长无痴呆和无残疾生存期。虽然干预期已经结束，但这个庞大而多样化的队列的建立，加上干预期前所未有的发现，为继续监测重要的健康结局和危及老年人群无残疾生存的前因创造了难得的机会;特别是ADRD和癌症。将每年从受试者中收集个人健康信息，并通过为ADRD（以及阿尔茨海默病和非ADRD的亚型分类）、癌症（事件、转移、类型、分期和死亡）和其他关键健康结局（包括死亡）的专家裁定准备的病例文件确认主要临床事件。ASPREE等大型长期老化研究的观察性随访受益于ADRD专业知识的连续性、经验和领导力。在这份资金申请中，ASPREE领导团队建议将美国和澳大利亚参与者的随访时间延长五年（即，“ASPREE-XT”），这将极大地丰富一个已经独特的，非常有价值的国际研究资产，专注于延长老年人的健康独立生活，没有痴呆症和残疾。实现这一目标所需的基础设施将依赖于美国和澳大利亚协调中心的连续性、领导力和经验，这些协调中心通过示范性研究的实施和完成证明了其在ASPREE试验中的成功。这包括两国标准化的培训和认证，以确保年度认知电池和触发痴呆评估的一致管理，其中包括阿尔茨海默病评估量表认知子量表。Bi-National行政核心将部署必要的基础设施和管理，以实现ASPREE-XT纵向队列研究的目标，包括了解低剂量阿司匹林对认知能力下降、ADRD、残疾和癌症预防的影响。Bi-National行政核心的总体目标是促进来自所有核心的信息，想法和数据的动态交流，以深入了解可能延长老年人无痴呆和无残疾生存的因素。